Ingersoll Rand has expanded its automation capabilities through a strategic acquisition of Scinomix, a company specializing in laboratory automation systems used in life sciences and research environments.
This move represents a significant transformation for Ingersoll Rand, shifting its focus beyond traditional industrial equipment such as compressors and flow systems into high-precision automation markets.
The acquisition strengthens the company’s position in fast-growing sectors such as biotechnology, pharmaceutical research, and clinical diagnostics.
Laboratory automation is increasingly important in modern science and healthcare industries. Demand for high-throughput testing, sample traceability, and workflow efficiency is driving rapid adoption of automated systems.
Scinomix technologies focus on:
These systems reduce manual errors and improve processing speed in research and diagnostic environments.

By combining industrial engineering expertise with laboratory automation technologies, Ingersoll Rand is creating a hybrid automation model that spans both heavy industry and precision environments.
This integration enables:
It also allows cross-industry innovation between industrial manufacturing and life sciences automation.
Modern automation systems increasingly rely on digital connectivity and data-driven decision-making.
Ingersoll Rand continues to enhance system intelligence by integrating monitoring, diagnostics, and predictive analytics into its automation platforms.
This enables operators to optimize performance, reduce downtime, and improve maintenance planning across both industrial and laboratory environments.
Ingersoll Rand automation technologies are used in:
Each sector benefits from improved efficiency, precision, and operational reliability.